Business Context and Reporting Period
Company: Armata Pharmaceuticals, Inc. (ARMP)
Filing Type: Form 8-K (Current Report)
Date: August 26, 2024
Context: The filing discloses a poster presentation and corporate presentation regarding the Company's expected participation in the 2024 Military Health System Research Symposium held in Kissimmee, Florida.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses solely on regulatory disclosure of non-financial corporate presentations.
Material Changes and Updates
- Enrollment Update: The Company corrected a figure in its Poster Presentation (Exhibit 99.1). The enrollment percentage for a specific project was updated from approximately 75% to 80%.
- Timeline Projection: The updated enrollment figure maintains the projection that completion is expected in Q4 2024.
- Document Replacement: A new Corporate Presentation dated August 26, 2024, replaces the version posted on August 16, 2024.
Guidance, Outlook, and Risks
Outlook: The Company anticipates completing the referenced project in Q4 2024 based on the updated 80% enrollment figure.
Management Commentary: The Company notes that the Poster Presentation was printed prior to the availability of updated figures. Future updates to the Corporate Presentation may be disseminated via the Company's website without a subsequent Form 8-K filing.
Risks and Disclaimers: The information provided is summary in nature and is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. The Company undertakes no obligation to update the information except as required by federal securities laws.
Investor Verification Checklist
- Verify the updated enrollment status (80%) and Q4 2024 completion projection in the latest Corporate Presentation (Exhibit 99.3).
- Review the Poster Presentation (Exhibit 99.1) to understand the context of the corrected data point.
- Monitor the Company's investor relations website for future updates to the Corporate Presentation, as these may not be accompanied by additional 8-K filings.
- Confirm that no financial metrics were disclosed in this specific filing; refer to recent 10-Q or 10-K filings for financial health data.